McCully, KS. Homocysteine and vascular disease. Nat Med 1996;2: 386–389.
Schroecksnadel, K, Frick, B, Wirleitner, B, et al. Moderate hyperhomocysteinemia and immune activation. Curr Pharm Biotechnol 2004;5: 107–118.
Lawrence de Koning, AB, Werstuck, GH, Zhou, J, et al. Hyperhomocysteinemia and its role in the development of atherosclerosis. Clin Biochem 2003;36: 431–441.
Hankey, GJ, Eikelboom, JW. Homocysteine levels in patients with stroke: Clinical relevance and therapeutic implications. CNS Drugs 2001;15: 437–443.
Aksu, K, Turgan, N, Oksel, F, et al. Hyperhomocysteinaemia in Behcet's disease. Rheumatology (Oxford) 2001;40: 687–690.
Petri, M, Roubenoff, R, Dallal, GE, et al. Plasma homocysteine as a risk factor for atherothrombotic events in systemic lupus erythematosus. Lancet 1996;348: 1120–1124.
Roubenoff, R, Dellaripa, P, Nadeau, MR, et al. Abnormal homocysteine metabolism in rheumatoid arthritis. Arthritis Rheum 1997;40: 718–722.
Vrethem, M, Mattsson, E, Hebelka, H, et al. Increased plasma homocysteine levels without signs of vitamin B12 deficiency in patients with multiple sclerosis assessed by blood and cerebrospinal fluid homocysteine and methylmalonic acid. Mult Scler 2003;9: 239–245.
Weiss, N, Heydrick, SJ, Postea, O, et al. Influence of hyperhomocysteinemia on the cellular redox state—Impact on homocysteine-induced endothelial dysfunction. Clin Chem Lab Med 2003;41: 1455–1461.
Stanger, O, Weger, M. Interactions of homocysteine, nitric oxide, folate and radicals in the progressively damaged endothelium. Clin Chem Lab Med 2003;41: 1444–1454.
Hajjar, KA. Homocysteine: A sulphrous fire. J Clin Invest 2001;107: 663–664.
Feigin, VL, Anderson, CS, Mhurchu, CN. Systemic inflammation, endothelial dysfunction, dietary fatty acids and micronutrients as risk factors for stroke: A selective review. Cerebrovasc Dis 2002;13: 219–224.
Stuhlinger, MC, Oka, RK, Graf, EE, et al. Endothelial dysfunction induced by hyperhomocyst(e)inemia: Role of asymmetric dimethylarginine. Circulation 2003;108: 933–938.
Fiocchi, C. Intestinal inflammation: A complex interplay of immune and nonimmune cell interactions. Am J Physiol 1997;273: G769–G775.
Hatoum, OA, Miura, H, Binion, DG. The vascular contribution in the pathogenesis of inflammatory bowel disease. Am J Physiol Heart Circ Physiol 2003;285: H1791–H1796.
Laroux, FS, Grisham, MB. Immunological basis of inflammatory bowel disease: Role of the microcirculation. Microcirculation 2001;8: 283–301.
Fiocchi, C. Inflammatory bowel disease: Etiology and pathogenesis. Gastroenterology 1998;115: 182–205.
Fiocchi, C, Ina, K, Danese, S, et al. Alterations of the mucosal immune system in IBD mesenchymal and endothelial cells. In: Immune Mechanisms in Inflammatory Bowel Disease. Landes Bioscience Publishers, 2003.
Fiocchi, C. From immune activation to gut tissue injury: The pieces of the puzzle are coming together. Gastroenterology 1999;117: 1238–1241.
Cattaneo, M, Vecchi, M, Zighetti, ML, et al. High prevalence of hyperchomocysteinemia in patients with inflammatory bowel disease: A pathogenic link with thromboembolic complications? Thromb Haemost 1998;80: 542–545.
Koutroubakis, IE, Dilaveraki, E, Vlachonikolis, IG, et al. Hyperhomocysteinemia in Greek patients with inflammatory bowel disease. Dig Dis Sci 2000;45: 2347–2351.
Mahmud, N, Molloy, A, McPartlin, J, et al. Increased prevalence of methylenetetrahydrofolate reductase C677T variant in patients with inflammatory bowel disease, and its clinical implications. Gut 1999;45: 389–394.
Papa, A, De Stefano, V, Danese, S, et al. Hyperhomocysteinemia and prevalence of polymorphisms of homocysteine metabolism-related enzymes in patients with inflammatory bowel disease. Am J Gastroenterol 2001;96: 2677–2682.
Romagnuolo, J, Fedorak, RN, Dias, VC, et al. Hyperhomocysteinemia and inflammatory bowel disease: Prevalence and predictors in a cross-sectional study. Am J Gastroenterol 2001;96: 2143–2149.
Vasilopoulos, S, Saiean, K, Emmons, J, et al. Terminal ileum resection is associated with higher plasma homocysteine levels in Crohn's disease. J Clin Gastroenterol 2001;33: 132–136.
Morgenstern, I, Raijmakers, MT, Peters, WH, et al. Homocysteine, cysteine, and glutathione in human colonic mucosa: Elevated levels of homocysteine in patients with inflammatory bowel disease. Dig Dis Sci 2003;48: 2083–2090.
Harvey, RF, Bradshaw, JM. A simple index of Crohn's-disease activity. Lancet 1980;1: 514.
Sutherland, LR, Martin, F, Greer, S, et al. 5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology 1987;92: 1894–1898.
Sgambato, A, Migaldi, M, Montanari, M, et al. Dystroglycan expression is frequently reduced in human breast and colon cancers and is associated with tumor progression. Am J Pathol 2003;162: 849–860.
Sturm, A, Leite, Z, Danese, S, et al. Divergent cell cycle kinetics underlie the distinct functional capacity of mucosal T-cells in Crohn's disease and ulcerative colitis. Gut (in press).
Danese, S, de La Motte, C, Sturm, A, et al. Platelets trigger a CD40-dependent inflammatory response in the microvasculature of inflammatory bowel disease patients. Gastroenterology 2003;124: 1249–1264.
Danese, S, Katz, J, Saibeni, S, et al. Activated platelets are the source of elevated levels of soluble CD40 ligand in the circulation of inflammatory bowel disease patients. Gut 2003: 1435–1441.
Danese, S, de la Motte, C, Reyes, BM, et al. Cutting edge: T cells trigger CD40-dependent platelet activation and granular RANTES release: A novel pathway for immune response amplification. J Immunol 2004;172: 2011–2015.
Vogel, JD, West, GA, Danese, S, et al. CD40-mediated immune-nonimmune cell interactions induce mucosal fibroblast chemokine leading to T-cell trasmigration. Gastroenterology 2004: 63–80.
Schroecksnadel, K, Frick, B, Wirleitner, B, et al. Homocysteine accumulates in supernatants of stimulated human peripheral blood mononuclear cells. Clin Exp Immunol 2003;134: 53–56.
Nilsen, EMJF, Jahnsen, FL, Lundin, KE, et al. Cytokine profiles of cultured microvascular endothelial cells from the human intestine. Gut 1998;42: 635–642.
Yadav, R, Larbi, KY, Young, RE, et al. Migration of leukocytes through the vessel wall and beyond. Thromb Haemost 2003;90: 598–606.
Panes, J, Granger, DN. Leukocyte-endothelial cell interactions: molecular mechanisms and implications in gastrointestinal disease. Gastroenterology 1998;114: 1066–1090.
Schroecksnadel, K, Frick, B, Winkler, C, et al. Hyperhomocysteinemia and immune activation. Clin Chem Lab Med 2003;41: 1438–1443.
Lee, H, Kim, HJ, Kim, JM, et al. Effects of dietary folic acid supplementation on cerebrovascular endothelial dysfunction in rats with induced hyperhomocysteinemia. Brain Res 2004;996: 139–147.
Mattson, MP, Haberman, F. Folate and homocysteine metabolism: Therapeutic targets in cardiovascular and neurodegenerative disorders. Curr Med Chem 2003;10: 1923–1929.
Doshi, S, McDowell, I, Moat, S, et al. Folate improves endothelial function in patients with coronary heart disease. Clin Chem Lab Med 2003;41: 1505–1512.
Ghosh, S, Goldin, E, Gordon, FH, et al. Natalizumab for active Crohn's disease. N Engl J Med 2003;348: 24–32.
Binion, DG, West, GA, Ina, K, et al. Enhanced leukocyte binding by intestinal microvascular endothelial cells in inflammatory bowel disease. Gastroenterology 1997;112: 1895–1907.
Binion, DG, West, GA, Volk, EE, et al. Acquired increase in leucocyte binding by intestinal microvascular endothelium in inflammatory bowel disease. Lancet 1998;352: 1742–1746.
Papa, A, Santoliquido, A, Danese, S, et al. Increased thickness of the arterial intima-media detected by utrasonography in patients with IBD. Dig Liv Dis 2004;(suppl 2):PO 329.